Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1515       
Year : 2014  |  Volume : 140  |  Issue : 1  |  Page : 69-76

Expression of galectin-3 in gastric adenocarcinoma

1 Department of Pathology, Federal University of São Paulo, SP, Brazil
2 Oncology Group, Division of Gastroenterology, Department of Medicine, Federal University of São Paulo, SP, Brazil
3 Department of Biosciences, Federal University of São Paulo, SP, Brazil

Correspondence Address:
Daniel Araki Ribeiro
Department of Biosciences, Federal University of São Paulo- UNIFESP Av. Ana Costa, 95, Vila Mathias, Santos - SP, 11060-001
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 25222780

Rights and PermissionsRights and Permissions

Background & objectives: Galectin-3 a member of the galectin family is an endogenous β-galactoside binding lectin. It has been found to be associated with cell adhesion, recognition, proliferation, differentiation, immunomodulation, angiogenesis, apoptosis and can be a reliable marker for cancer aggressiveness. The aim of this study was to verify protein expression in gastric adenocarcinoma tissues and correlate the results with the clinical aspects in the study population. Methods: Galectin-3 expression was examined by immunohistochemistry in 57 samples of gastric adenocarcinomas tissues. Galectin-3 protein expression was observed in the cytoplasm and the nucleus of examined tissues. Results: Thirty one (54.4%) samples had strong or moderate staining and 26 (45.6%) tumours had negative or weak staining. The galectin-3 did not show association with the sex ( p =0.347), age ( p =0.999), Lauren's classification ( p =0.731) and TNM stage ( p =0.222). Regarding the TNM stage, 66.7 per cent of stage I tumours had strong or moderate staining; with tumours stage IV this percentage was 33.3 per cent. Interpretation & conclusion: Our results suggest that gal-3 is not a reliable biomarker for prognosis of the gastric adenocarcinoma by immunohistochemistry. Further studies need to be done on a large sample of tumour tissues in different clinical staging.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded329    
    Comments [Add]    

Recommend this journal